Therapeutic Advances in Ophthalmology最新文献

{"title":"Targeting retinal angiogenesis: sex differences in adverse reactions to anti-VEGF therapies.","authors":"Eleonora Castellana, Maria Rachele Chiappetta","doi":"10.1177/25158414251359587","DOIUrl":"10.1177/25158414251359587","url":null,"abstract":"","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":"17 ","pages":"25158414251359587"},"PeriodicalIF":2.3,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12290349/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144733426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Infectious scleritis: a comprehensive narrative review of epidemiology, clinical characteristics, and management strategies.","authors":"Hamidreza Ghanbari, Masoud Rahimi, Ali Momeni, Kiana Hassanpour, Nikoo Bayan, Karen E Lee, Alex Hansen, Ali R Djalilian, Christopher J Rapuano, Mohammad Soleimani","doi":"10.1177/25158414251357776","DOIUrl":"10.1177/25158414251357776","url":null,"abstract":"<p><p>This study aims to provide an update on infectious scleritis (IS). A comprehensive search was conducted using Google Scholar, Scopus, and PubMed. IS is a rare but critical condition that presents significant diagnostic challenges and often leads to poor visual outcomes. It accounts for approximately 5%-10% of scleritis cases and warrants significant attention due to its delayed diagnosis. Ocular surgery is the primary contributor to IS, accounting for a substantial proportion of cases ranging from 58% to 83%, followed by trauma contributing to approximately 10% of cases. IS can be caused by various microorganisms, including bacteria (86%-87%), fungi (11%-13%), viruses, and parasites. Conjunctival hyperemia is a prevalent manifestation in approximately 98% of IS cases, while scleral necrosis is observed in around 93% of cases. Distinguishing IS from inflammatory scleritis before initiating steroid treatment is crucial. Surgical debridement of infected tissue, accompanied by appropriate topical and systemic antibiotic therapy significantly improves treatment outcomes by removing infected tissue and reducing the infection burden. Early surgical intervention markedly increases the likelihood of preserving the eye globe in severe cases. Risk factors for poor visual outcomes include poor visual acuity at presentation, associated endophthalmitis, keratitis, fungal etiology, and medical therapy without surgical debridement. Early diagnosis of IS is crucial as the disease can progress rapidly and lead to vision loss. While bacterial infections are the most common etiology of IS, the prognosis is particularly poor in cases of fungal IS. Surgical interventions, when combined with appropriate medical treatment, improve outcomes.</p>","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":"17 ","pages":"25158414251357776"},"PeriodicalIF":2.3,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12290352/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144733425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bilateral intraocular masses in a child as a first presentation of disseminated tuberculosis: case report.","authors":"Doaa Maamoun Ashour, Nada Abdel Salam Abdel Aziz, Khadiga Eltonbary, Noha Abdul Khaliq, Yasmeen Abdelaziz Fereig","doi":"10.1177/25158414251356373","DOIUrl":"10.1177/25158414251356373","url":null,"abstract":"<p><p>An 8-year-old girl presented with left leukocoria, prompting an evaluation that revealed bilateral intraocular masses, including a right upper nasal choroidal lesion and a large left heterogeneous mass with exudative detachment. Imaging and systemic assessment uncovered multiple intracranial lesions, miliary lung lesion, a facial lesion, and a right tibial lesion. A strongly positive tuberculin test and a history of close contact with a tuberculosis (TB) patient led to the diagnosis of disseminated TB. Treatment with anti-tuberculosis therapy and systemic steroids initially resulted in improvement, including regression of the ocular tuberculomas and enhanced visual acuity. However, the patient developed severe headache due to non-communicating obstructive hydrocephalus, necessitating surgical intervention. Despite intensive care, the patient ultimately succumbed to the condition. This case highlights that ocular TB lesions can mimic intraocular tumors and underscores the importance of comprehensive evaluation, including multimodal imaging and systemic work-up, for early diagnosis and management of disseminated TB.</p>","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":"17 ","pages":"25158414251356373"},"PeriodicalIF":2.3,"publicationDate":"2025-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256744/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144638083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plain language summary of publication of the 48-week results from the PHOTON study: intravitreal aflibercept 8 mg for diabetic macular edema.","authors":"David M Brown, David S Boyer, Diana V Do, Charles C Wykoff, Taiji Sakamoto, Peter Win, Sunir Joshi, Hani Salehi-Had, András Seres, Alyson J Berliner, Sergio Leal, Robert Vitti, Karen W Chu, Kimberly Reed, Rohini Rao, Yenchieh Cheng, Delia Voronca, Rafia Bhore, Ursula Schmidt-Ott, Thomas Schmelter, Andrea Schulze, Xin Zhang, Sobha Sivaprasad","doi":"10.1177/25158414251347689","DOIUrl":"https://doi.org/10.1177/25158414251347689","url":null,"abstract":"&lt;p&gt;&lt;p&gt;What is this summary about? This is a summary of a publication about the PHOTON study, which was published in &lt;i&gt;The Lancet&lt;/i&gt;.&lt;b&gt;Diabetic macular edema&lt;/b&gt; (DME) is a serious and common complication of diabetes, with an estimated global prevalence of 5.5% in people with diabetes.In DME, leaky blood vessels lead to the swelling (or &lt;b&gt;edema&lt;/b&gt;) of the macula (the area of the retina at the back of the eye that is responsible for sharp vision), which can then lead to blurred vision and vision loss. Over-production of a protein called vascular endothelial growth factor (VEGF) is a main cause of these leaky blood vessels.To directly address the underlying problem, anti-vascular endothelial growth factor (anti-VEGF) medicine, given as an injection into the eye, can block the VEGF causing the leaky blood vessels and &lt;b&gt;edema&lt;/b&gt;.○ However, frequent eye injections are often required to maintain good vision and many people find it difficult to keep up with the visits and injections.&lt;b&gt;Aflibercept&lt;/b&gt; is an anti-VEGF medicine that is approved for the treatment of DME.○ It is recommended that people with DME receive injections of &lt;b&gt;aflibercept&lt;/b&gt; 2 mg every 4-8 weeks after 5 initial monthly injections.The PHOTON study was carried out to determine if a higher, 8-mg dose of &lt;b&gt;aflibercept&lt;/b&gt;, given every 12 or 16 weeks after 3 initial monthly injections, could provide the same treatment benefits as &lt;b&gt;aflibercept&lt;/b&gt; 2 mg, given every 8 weeks after 5 initial monthly injections. What were the results? During the first year (or at 48 weeks) of the study, participants who received &lt;b&gt;aflibercept&lt;/b&gt; 8 mg every 12 or 16 weeks following 3 initial monthly injections had similar improvements in vision when compared to those treated with &lt;b&gt;aflibercept&lt;/b&gt; 2 mg every 8 weeks following 5 initial monthly injections with fewer injections.○ Most participants who received &lt;b&gt;aflibercept&lt;/b&gt; 8 mg and completed the study through 48 weeks kept their 12- or 16-week injection schedules without needing to have more frequent injections.○ Disease severity, measured by the &lt;b&gt;Diabetic&lt;/b&gt; Retinopathy Severity Scale score, improved by at least 2 levels at week 48 in 27% of participants who received &lt;b&gt;aflibercept&lt;/b&gt; 2 mg every 8 weeks, 29% of participants who received &lt;b&gt;aflibercept&lt;/b&gt; 8 mg every 12 weeks, and 20% of participants who received &lt;b&gt;aflibercept&lt;/b&gt; 8 mg every 16 weeks.○ Participants who received &lt;b&gt;aflibercept&lt;/b&gt; 8 mg had similar decreases in swelling of the &lt;b&gt;macula&lt;/b&gt; as measured by central retinal thickness compared to those treated with &lt;b&gt;aflibercept&lt;/b&gt; 2 mg at week 48, even though fewer injections were received with &lt;b&gt;aflibercept&lt;/b&gt; 8 mg.Adverse events in participants treated with &lt;b&gt;aflibercept&lt;/b&gt; 8 mg were also similar to those treated with &lt;b&gt;aflibercept&lt;/b&gt; 2 mg. What do the results mean? Often, patients with DME may find it difficult to keep up with the routine medical appointments that are required to maintain their vision.Findings show","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":"17 ","pages":"25158414251347689"},"PeriodicalIF":2.3,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12255855/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144627112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Addressing chronic visual hallucination by multimodal retinal imaging: a CBS case.","authors":"Yvonne O'Neill, Alessandro Arrigo, Paulo-Eduardo Stanga","doi":"10.1177/25158414251320032","DOIUrl":"10.1177/25158414251320032","url":null,"abstract":"<p><p>Charles Bonnet syndrome (CBS) is characterised by visual hallucinations in individuals with significant visual impairment. This literature review and case report focus on the unique presentation of CBS in an 82-year-old woman with age-related macular degeneration, who experienced visual hallucinations for over 10 years. The aim is to raise awareness of CBS among healthcare professionals and the public, addressing the diagnostic challenges that contribute to its underdiagnosis and mismanagement. A literature review was conducted to assess the prevalence and diagnosis of CBS. Databases including Google Scholar and PubMed were searched using the terms 'Charles Bonnet Syndrome', 'Case report' and 'Diagnosis'. The patient reported a range of visual hallucinations, from simple geometric shapes to highly detailed figures. A diagnosis of CBS was made based on her visual impairment and the nature of the hallucinations. No treatment was required, and the patient was reassured that the hallucinations were benign and unrelated to any psychiatric or neurological disorder. This case highlights the diagnostic challenges associated with CBS, which is often misdiagnosed or overlooked due to its rarity and the hesitancy of patients to disclose their symptoms. The long period of unreported hallucinations in this case emphasises the need for greater awareness among healthcare providers, enabling earlier recognition of CBS and differentiation from other conditions. The wide range of hallucination types seen in CBS adds to the complexity of the syndrome. The key takeaway is that increased awareness and recognition of CBS are essential for proper diagnosis, reducing patient anxiety and avoiding unnecessary treatments. This case contributes to the existing literature by illustrating the broad spectrum of CBS presentations and advocating for enhanced education on the condition.</p>","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":"17 ","pages":"25158414251320032"},"PeriodicalIF":2.3,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12246525/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144627111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Repeated corneal crosslinking for progressive keratoconus: efficiency and safety.","authors":"Eleftherios Chatzimichail, Georgios Chondrozoumakis, Farideh Doroodgar, Efstathios Vounotrypidis, Georgios D Panos, Nicolas Feltgen, Zisis Gatzioufas","doi":"10.1177/25158414251350071","DOIUrl":"10.1177/25158414251350071","url":null,"abstract":"<p><p>Corneal crosslinking (CXL) was first introduced in clinical practice in 2003. Since then, this procedure has been established as the first-line treatment in the management of progressive keratoconus. Over the last years, many different protocols have emerged, each one of them with variable clinical outcomes and safety profile. Progression of keratoconus after primary CXL is very rare, but it has been reported in the literature. This review summarises the existing data on repeated CXL after primary failure, emphasising on clinical efficacy and safety.</p>","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":"17 ","pages":"25158414251350071"},"PeriodicalIF":2.3,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12206266/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144529662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The added effect of preoperative nepafenac on pain and discomfort following alcohol-assisted photorefractive keratectomy.","authors":"Eliya Levinger, Nir Gomel, Ami Hirsh, Maya Tenne, Asaf Achiron, Nadav Levinger, Shmuel Levinger, Nadav Shemesh, Adi Abulafia, Michael Mimouni, Nir Sorkin","doi":"10.1177/25158414251349340","DOIUrl":"10.1177/25158414251349340","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the effect of preoperative nepafenac on pain following alcohol-assisted photorefractive keratectomy (PRK).</p><p><strong>Settings: </strong>Tel-Aviv Sourasky Medical Center-a tertiary medical center.</p><p><strong>Design: </strong>Observational case-series.</p><p><strong>Methods: </strong><i>Setting</i>: Refractive center. <i>Study Population</i>: 205 PRK patients grouped randomly into five according to pain-management protocols: (1) paracetamol/ibuprofen (Parac-Ibupr group, <i>n</i> = 39), (2) high-dose oxycodone/naloxone only (Oxy-only group, <i>n</i> = 45), (3) oxycodone/naloxone and postoperative 0.1%-nepafenac (Oxy-Nep group, <i>n</i> = 36), (4) oxycodone/naloxone and preoperative and postoperative 0.1%-nepafenac (Nep-Oxy-Nep group, <i>n</i> = 42), and (5) preoperative and postoperative 0.1%-nepafenac only (Nep-only group, <i>n</i> = 43). Preoperative nepafenac was administered three times daily for 2 days. <i>Main Outcome Measures</i>: Mean and maximal pain levels (postop days 1-5), duration of tearing/photophobia, number of pain tablets taken, uncorrected visual acuity (UCVA), side effects and epithelial healing delay.</p><p><strong>Results: </strong>Mean pain scores differed significantly between groups (<i>p</i> < 0.001)-lowest in groups receiving preop nepafenac (Nep-only: 1.8 ± 1.6, Nep-Oxy-Nep: 2.3 ± 1.5) compared to the Oxy-Nep (3.2 ± 1.9), Oxy-only (3.8 ± 1.7), and Parac-Ibupr (4.8 ± 1.6) groups. Similar findings were observed with maximal pain scores. Total number of pain tablets taken was lowest in the Nep-only group. Duration of photophobia was shortest in groups receiving preoperative nepafenac (<i>p</i> < 0.001). Duration of tearing was longest in the Parac-Ibupr group (<i>p</i> < 0.001). Nausea/vomiting occurred in 20% of the Oxy-only group (<i>p</i> < 0.001). There were four cases of delayed epithelial healing-all in groups not treated with nepafenac. One-month UCVA did not differ between groups. No additional independent factors were found to be associated with pain except age.</p><p><strong>Conclusion: </strong>Adding preoperative nepafenac significantly reduced pain and photophobia with complete epithelial healing. Addition of oral opiates to nepafenac treatment had little analgetic benefit.</p>","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":"17 ","pages":"25158414251349340"},"PeriodicalIF":2.3,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12188066/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144498084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation of intravitreal IL-6 with the formation of epiretinal membrane after successful retinal detachment repair.","authors":"Konstantinos Ananikas, Panagiotis Stavrakas, Christos Kroupis, Evita Evangelia Christou, Stratos V Gotzaridis, Panagiotis Dervenis, Dimitrios Papaconstantinou","doi":"10.1177/25158414251350072","DOIUrl":"10.1177/25158414251350072","url":null,"abstract":"<p><strong>Introduction: </strong>Epiretinal membrane (ERM) formation following a successful rhegmatogenous retinal detachment (RRD) operation has been reported to occur in about 4%-15% of the cases. In this study, we collected vitreous samples from patients with RRD to identify whether the concentration of IL-6 is correlated with the presence of postoperative ERM. We aim is to identify whether the inflammatory cascade could be a potential key factor in the ERM pathogenesis.</p><p><strong>Methods: </strong>This was a prospective single-centre study where 42 eyes were enrolled. All patients underwent 25G PPV. The vitreous sample was collected before the infusion line was opened so that the sample would not be diluted. Then, the sample was centrifuged at 5000 g for 15 min at 15°C. Afterwards, the supernatant fluid was transferred to an Eppendorf tube and stored at -40°C. Electrochemiluminescence immunoassay (ECLIA) was employed for the measurement of IL-6 concentration (pg/ml). All patients had optical coherence tomography (OCT) scans at the macula at 4 weeks, 3 months and 1 year after primary RRD repair to identify the presence of the ERM.</p><p><strong>Results: </strong>All patients had a follow-up of at least 12 months. The mean BCVA of all 42 eyes at the end of follow-up period was 0.24 ± 0.31 LogMar. The presence of ERM was identified in 28.6% (<i>n</i> = 12) of the patients, and the mean IL-6 concentration was 573.96 ± 1179.58 pg/ml. It appears that the patients who developed a post op ERM had an IL-6 mean concentration value of 173.96 ± 191.25 pg/ml, and the patients with no post op ERM had 733.97 ± 1364.04 pg/ml with <i>p</i>-value = 0.04 < 0.05. Nevertheless, following a multivariate binary logistic regression model, the above results did not appear to be statistically significant.</p><p><strong>Conclusion: </strong>High concentration of IL-6 in the vitreous of eyes with RRD does not hold a significant role in the ERM pathogenesis. Our study identified the presence of a draining retinotomy as the most significant risk factor for ERM formation following a successful surgical RRD repair.</p>","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":"17 ","pages":"25158414251350072"},"PeriodicalIF":2.3,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12182604/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144476791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in IOL calculations in patients with keratoconus.","authors":"Assaf Gershoni, Graham D Barrett, Ruti Sella","doi":"10.1177/25158414251348882","DOIUrl":"10.1177/25158414251348882","url":null,"abstract":"<p><p>Keratoconus is a progressive ectatic corneal disease characterized by corneal thinning, steepening, and irregular astigmatism, presenting unique challenges for intraocular lens (IOL) calculations in cataract surgery. The use of traditional formulas for IOL calculations in eyes with keratoconus frequently leads to significant refractive prediction errors, often resulting in a hyperopic shift, which can lead to suboptimal outcomes and reduced patient satisfaction. This review examines the impact of keratoconus on IOL calculations and highlights recent advancements in formulas specifically designed for eyes with keratoconus, particularly the Barrett True-K and the Kane Keratoconus formulas. We assess the effectiveness of these formulas based on the current literature and provide clinical recommendations aimed at improving surgical outcomes in this complex patient group.</p>","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":"17 ","pages":"25158414251348882"},"PeriodicalIF":2.3,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12182609/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144476781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stem cell therapy as treatment for Stargardt disease.","authors":"Erica Marks, Adith Anugu, Joseph Bisiani, Srinivas Pentyala","doi":"10.1177/25158414251320592","DOIUrl":"10.1177/25158414251320592","url":null,"abstract":"<p><p>Stargardt disease or Juvenile Macular Degeneration is a rare genetic disorder caused by a mutation in the ABCA4 gene that results in degeneration of the macula and loss of central vision. The mutation in the ABCA4 gene causes a build-up of lipofuscin, which is a substance that is left over from the breakdown and absorption of damaged blood cells. This build-up of lipofuscin causes the death of photoreceptor cells and the subsequent degeneration of the macula. Due to the nature of Stargardt's disease, there are currently no cures or treatment options. However, in recent years, there has been an increase in research and exploration of utilizing stem cell therapy as a potential cure and treatment for Stargardt disease. Growing research in the field of ophthalmology has found that the use of stem cells can potentially replace the loss of photoreceptor cells, slow the progression of the degeneration of vision, and be a potential new treatment option for Stargardt disease.</p>","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":"17 ","pages":"25158414251320592"},"PeriodicalIF":2.3,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12102558/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144143712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}